Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer

Paul Cottu, Tomas Pascual, Jerôme Lemonnier, Huilin Hu, Estelle Roux, Roisin M. Connolly, Cynthia X. Ma, Antonio C. Wolff, Thayane Crestani, Pablo Tolosa, Juan M. Ferrero-Cafiero, Antonio Mulero-Sánchez, Fernando Salvador, Guillermo Villacampa, Joaquín Gavilá, Thibault de La Motte Rouge, Aleix Prat

Therapeutic Advances in Medical Oncology

Published online on August 13, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Despite advances in endocrine therapy, patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (eBC) remain at risk of recurrence (ROR). Chemotherapy is often used in high-risk ...